{
  "data": {
    "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFK",
    "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFK",
    "indicator": {
      "slug": "dupixent-sales-annual",
      "name": "Dupixent sales (annual)",
      "definition": "Total net sales revenue generated by Dupixent (dupilumab)."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "period": {
      "start": "2030-01-01",
      "end": "2030-12-31",
      "type": "year"
    },
    "value": 25,
    "value_text": "around €25 billion",
    "unit": "EUR",
    "currency": "EUR",
    "scale": "billion",
    "value_type": "forecast",
    "source": {
      "org": "Sanofi",
      "org_short_name": "Sanofi",
      "org_url": "https://www.sanofi.com",
      "org_tier": 2,
      "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
      "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767",
      "document_type": "press_release",
      "locator": "Belén Garijo, Chief Executive Officer",
      "quote": "My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements. We have taken the first decisive steps on pipeline prioritisation and recently, we appointed a focused Executive Committee aligned with the strategic priorities. Looking ahead, we're confident in our trajectory of profitable growth: Dupixent sales are now expected to reach around €25 billion in 2030, complemented by approximately €10 billion from Pharma launches — both at constant exchange rates. This strong financial foundation is expected to support continued pipeline enhancement and external growth opportunities in the years ahead. We are committed to acting and reporting on our progress to shareholders and other stakeholders in the quarters to come.",
      "published_date": "2026-07-30",
      "accessed_at": "2026-09-15",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-15T22:15:46.809Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFK",
      "bibtex": "@misc{sanofi2026dupixentbjmgfk,\n  author       = {{Sanofi}},\n  title        = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFK},\n  note         = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}"
    },
    "updated_at": "2026-09-15T22:15:46.809Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}